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Abstract
Background: Treatment for metastatic renal cell cancer (mRCC) has advanced dramatically with
understanding of the pathogenesis of the disease. New treatment options may provide improved
progression-free survival (PFS). We aimed to determine the relative effectiveness of new therapies
in this field.
Methods: We conducted comprehensive searches of 11 electronic databases from inception to
April 2008. We included randomized trials (RCTs) that evaluated bevacizumab, sorafenib, and
sunitinib. Two reviewers independently extracted data, in duplicate. Our primary outcome was
investigator-assessed PFS. We performed random-effects meta-analysis with a mixed treatment
comparison analysis.
Results: We included 3 bevacizumab (2 of bevacizumab plus interferon-a [IFN-a]), 2 sorafenib, 1
sunitinib, and 1 temsirolimus trials (total n = 3,957). All interventions offer advantages for PFS.
Using indirect comparisons with interferon-α as the common comparator, we found that sunitinib
was superior to both sorafenib (HR 0.58, 95% CI, 0.38–0.86, P = < 0.001) and bevacizumab + IFN-
a (HR 0.75, 95% CI, 0.60–0.93, P = 0.001). Sorafenib was not statistically different from bevacizumab
+IFN-a in this same indirect comparison analysis (HR 0.77, 95% CI, 0.52–1.13, P = 0.23). Using
placebo as the similar comparator, we were unable to display a significant difference between
sorafenib and bevacizumab alone (HR 0.81, 95% CI, 0.58–1.12, P = 0.23). Temsirolimus provided
significant PFS in patients with poor prognosis (HR 0.69, 95% CI, 0.57–0.85).
Conclusion: New interventions for mRCC offer a favourable PFS for mRCC compared to
interferon-α and placebo.
Background
Renal cell carcinoma results in an estimated 54,000 new
cases and 13,000 deaths each year in the United States [1].
Approximately 30% of patients present with metastatic
disease (mRCC), often associated with poor prognosis
and subsequent 5-year survival rate [2,3] Until recently,
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[IL-2] and interferon-alfa [IFN-α ]) that produce modest
response rates (< 20%) and substantial toxicities,
although occasional complete responses have been
reported [4]. Findings from randomized trials have shown
that treatment with cytokine therapy results in an overall
median survival of 13 months (range 6–28) [5].
As a greater understanding of the molecular mechanisms
involved in the pathogenesis of metastatic renal cell carci-
noma (mRCC) develops, more advanced treatment
options are emerging [4,6]. Clear-cell carcinoma histology
in particular, is associated with the von Hippel-Lindau
(VHL) tumour suppressor gene. Loss of this gene function
results in an over expression of several hypoxia-responsive
proteins, including the vascular endothelial growth factor
(VEGF) and platelet derived growth factor (PDGF), capa-
ble of promoting tumour growth and angiogenesis [7].
Newer antiangiogenesis-targeting agents are targeting
these factors and have recently provided more promising
treatment options. New VEGF targeted regimens (bevaci-
zumab, sorafenib, and sunitinib) and temsirolimus (CCI-
779), an inhibitor of mammalian target of rapamycin
(mTOR) kinase, in particular, have now been evaluated,
compared to interferon as a first-line treatment[6],
although they have not been directly evaluated in head-
to-head trials. Sunitinib and sorafenib have shown posi-
tive PFS endpoints when compared to IFN-α or placebo,
in phase III trials [8,9]. Similarly, phase III trials of beva-
cizumab plus interferon have shown superiority in PFS,
response, and tolerability compared with interferon alone
[4]. Temsirolimus has demonstrated positive PFS in
patients with a poor prognosis [10].
In a commentary in The Lancet, Motzer and Basch (2007)
highlight that important information on the clinical set-
ting, nature of the treatment program, and survival out-
comes is necessary to inform the management of patients
as well as future trial designs [6]. Other considerations
such as cost, patient experience, and adverse events also
have an important place in the decision-making process
and have complicated the delivery of these new interven-
tional drugs in some settings [11]. Thus, to determine
optimal treatment in a rapidly advancing era of targeted
therapy [6], we conducted a meta-analyses of all rand-
omized controlled trials examining either bevacizumab,
sorafenib, sunitinib or temsirolimus for the treatment of
mRCC. In the absence of head-to-head evaluations, we
applied an adjusted indirect comparison analysis [12].
Methods
Eligibility criteria
We included any randomized clinical trial evaluating the
therapeutic efficacy of VEGF inhibitors bevacizumab, sor-
afenib, or sunitinib, and the mTOR inhibitor tem-
sirolimus for the treatment of mRCC. Studies had to
evaluate one of the study drugs with a control interven-
tion. We included trials involving patients of any age, sex,
or mRCC stage. We included trials using the aforemen-
tioned study drugs as either sole treatment and as adjunct
treatment. We excluded pharmacokinetic studies, non-
randomized evaluations, early results presentations
(when later results were available), and animal/laboratory
studies.
Search Strategy
In consultation with an information specialist (PR), 2
searchers (EM, BR) developed search strategies. First, we
identified key terms of the study drugs with their trade
names. We then identified the various permutations of
mRCC listings in databases. The searches combined these
terms with the cancer MeSH heading "neoplasms" from
January 2008 to April 8th 2008. We searched independ-
ently, in duplicate (EM, BR), the following 11 databases
(from inception to April 8th 2008): AMED, CinAhl,
Cochrane Library (inception to issue 1, 2008), Embase,
and MedLine via PubMed. We sought unpublished stud-
ies through "clinicaltrials.gov", the UK National Research
Register and conference abstracts available from the
American Society of Clinical Oncology (ASCO) website,
which includes 18 annual conferences of ASCO and Gen-
itourinary Cancers Symposium, Gastrointestinal Cancers
Symposium, Breast Cancer Symposium, Prostate Cancer
Symposiums dating to before 2004. We supplemented
this search by reviewing the bibliographies of key papers.
Study selection and Data extraction
Two reviewers (BR and EM) independently extracted data
and appraised both quality and content. We conducted
data extraction using a standardized form (available from
corresponding author upon request). Initially, abstracts
were screened to exclude obviously ineligible reports, and
complete primary reports were reviewed for all remaining
studies. We classified trials and abstracts according to
study drug under investigation (i.e., bevacizumab, soraf-
enib, sunitinib, and temsirolimus) and obtained informa-
tion on patient characteristics, study design and therapy
duration. Study design items included methods of
sequence generation, allocation concealment, complete
description of who was blinded, use of intention-to-treat
analysis and whether the trial was stopped prior to the
planned duration, all methodological features capable of
impacting effect sizes [13,14] Our primary endpoint was
progression-free survival (PFS) as defined by investigators,
or where unavailable, by independent reviewers. We were
also interested in overall survival, median duration of
treatment and duration of treatment response, and the
overall response rate. Adverse events and details on deathsPage 2 of 9
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electronic database such that duplicate entries existed for
each study; when two entries did not match, we reached
consensus through discussion and 3rd party arbitration
(CO). To obtain full information regarding conference
abstracts, we attempted contact with the study authors for
full information through email and telephone communi-
cation.
Data analysis
In order to assess inter-rater reliability regarding eligibil-
ity, we calculated the Phi statistic (φ), which provides a
measure of inter-observer agreement independent of
chance [15] We calculated the hazard ratio (HR) and
appropriate 95% confidence intervals (CIs) of PFS accord-
ing to the HR reported in the original studies, communi-
cation with the authors, or through our own
recalculations. We used the last available report of each
study outcomes. We combined studies when more than
one trial of the four target drugs existed and were clinically
sensible. We pooled studies for each drug using the DerSi-
monian-Laird random effects model [16], which recog-
nizes and anchors studies as a sample of all potential
studies, and incorporates an additional between-study
component to the estimate of variability [17]. In the
absence of head-to-head evaluations, we conducted indi-
rect comparisons of the interventions versus similar com-
parators across similar patient groups using methods
described by Bucher et al [12]. This method maintains the
randomization from each trial and compares the sum-
mary estimates of pooled interventions with CIs. We used
forest plots to display the trial outcomes. We present the
geometric distribution of the indirect comparisons to dis-
play which comparisons were evaluated. We used SAS
(Cary, NC, version 9.0) for all analysis.
Results
Our primary literature search identified 150 full-length arti-
cles. There was excellent agreement between reviewers on
narrowing this to 16 full-text articles review (φ = 0.87). Of
these [11], were excluded as they were not original studies,
were not randomized controlled trials, did not examine at
least one of the selected drug therapies (i.e., bevacizumab,
sunitinib) or in one case, only examined outcomes in treat-
ment responders. The remaining 5 reports were included.
While numerous abstracts from relevant conferences and
annual meetings were reviewed, only 2 were included
[18,19] as they reported original studies. One of these [18]
was subsequently published in full during the review stage
of this manuscript and checked for accuracy [20] Addition-
ally, 9 abstracts examined reported on the preliminary find-
ings of 5 included studies [21-29] and were subsequently
excluded. Figure 1 displays the flow-diagram of the 7
included studies totalling 3,957 patients.
In total, 2 full-length studies [4,30] and 1 abstract [18]
examined bevacizumab; 1 full-length study [31] and 1
abstract [19] examined sorafenib; 1 full-length report [8]
presented follow-up data examining sunitinib for the
treatment of mRCC; and 1full-length report examined
temsirolimus [10]. Interferon-α was the most common
comparator in 5 included studies [4,18,19,8,10] while
placebos were used in 2 studies [23,9] Study and patient
population characteristics for each included trial are dis-
played in Additional File 1 [See Additional File 1].
While all included studies were randomized controlled
trials, among the 5 full-length articles, only 1 detailed the
sequence generation process [4] Only this same study ade-
quately described allocation concealment. Descriptions of
who was blinded were available in 3 studies [4,8,31]. All
5 full-length reports employed an intent-to-treat design in
their statistical analyses [4,8,30,31,10]. Finally, all 5 full
length reports described adequate safety monitoring, with
all five employing the use of a data and safety monitoring
board (DSMB) [4,8,30,31,10]. Four trials employed their
stopping rules [8,9,30,19]. Treatment outcomes by study
are displayed in Additional File 2 [See Additional File 2].
Meta-analysis of PFS
Five trials examined the new therapeutic interventions
compared to IFN-α for PFS. One trial evaluated tem-
sirolimus in patients with a poor prognosis. We pooled 2
trials that evaluated bevacizumab plus interferon versus
interferon alone (total n = 1,381) and found a pooled HR
of 0.68 (95% CI, 0.60–0.76, P = 0.001). We did not pool
the remaining studies as they had differing interventions.
Figure 2 displays the treatment versus IFN-α PFS out-
comes graphically and figure 3 displays the interventions
versus placebo. We did not pool study outcomes for sur-
vival.
Indirect comparisons of interventions versus IFN-  and 
placebo for PFS
Figure 4 displays the geometric distribution of the indirect
comparisons [32]. As the study evaluating temsirolimus
[10] included patients that were clinically different than
the other trials we did not include the temsirolimus pop-
ulation in our indirect comparison evaluation. When we
evaluated the treatment effects of sunitinib versus soraf-
enib, we identify superiority of sunitinib (HR 0.58, 95%
CI, 0.38–0.86, P = < 0.001) [8,19]. When we evaluate the
effect of sunitinib [8] versus bevacizumab plus inter-
feron[4,18], we identify the superiority of sunitinib (HR
0.75, 95% CI, 0.60–0.93, P = 0.001). When we evaluated
the effects of sorafenib [19] versus bevacizumab plus
interferon [4,18], we were unable to demonstrate signifi-
cant differences (HR 0.77, 95% CI, 0.52–1.13, P = 0.21).Page 3 of 9
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afenib and bevacizumab alone, with placebo as the simi-
lar comparator in previously treated patients through the
indirect comparison of two studies [9,23] We were unable
to display a significant difference (HR 0.81, 95% CI, 0.58–
1.12. P = 0.23). Figure 5 displays the comparisons graph-
ically.
Discussion
Our study should be of interest to patients and clinicians
alike. Until only recently, mRCC patients had few treat-
ment options beyond cytokine therapies. Our study dem-
onstrates consistent PFS benefits with the new targeted
therapies. Insights into the histology of RCC appear to
now result in considerably improved PFS and response
rates. Our study represents a first step at determining the
relative effectiveness of each new intervention.
We sought out all randomized controlled trials of targeted
drugs for mRCC. In the end, five papers and two abstracts
met our inclusion criteria. Analysis of the populations
from those studies revealed there to be three distinct
groups of patients: treatment naïve patients of favorable
to intermediate risk, refractory patients of favorable to
intermediate risk, and refractory patients of intermediate
to poor risk. As we hoped to measure the overall treatment
effect of targeted therapy, we included both the treatment
naïve and refractory patients of favorable to intermediate
risk. While the refractory group were likely to be enrolled
later after their time of diagnosis, and hence at risk for
shorter PFS by definition, we felt that PFS was still a rea-
sonable outcome measure based on their favorable (and
similar) prognostic risk. In a pooled analysis this would
likely bias the results in a negative direction that would
make a statistically positive result more likely to be true.
For patients with a poorer prognosis, PFS (our a priori pri-
mary endpoint) is likely shorter whether or not previous
treatment has been tried. Interestingly, as can be seen in
Additional Files 1 and 2 [See additional Files 1 and 2],
median duration of treatment and hazard ratios for PFS
and investigator assessed response rate were comparable
between the poor-risk patients and favorable-risk ones.
Establishing prognosis of mRCC is difficult as there are a
variety of patient, tumour, and biochemical factors that
have been shown to influence prognosis [33-35]. Some of
Flow diagram of included studiesigure 1
Flow diagram of included studies.Page 4 of 9
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Forest plot Hazard Rations (95% CI) of intervention versus IFN-α.
Forest plot Hazard Rations (95% CI) of intervention versus placeboigure 3
Forest plot Hazard Rations (95% CI) of intervention versus placebo.
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tissue pathology, tumour stage (nodes and number of
metastatic sites), serum calcium, alkaline phosphatase,
and hemoglobin values, and scores of performance such
as Eastern Co-operative Oncology Group (ECOG) per-
formance status or Karnofsky score. We accepted individ-
ual study authors' assessment of prognosis into favorable-
risk, intermediate, and poor-risk patients. While some cri-
teria varied between papers, measures of ECOG or Karnof-
sky scores were also used by authors and we accepted risk
stratification based upon them. From Additional Files 1
and 2 [See Additional Files 1 and 2], however, the PFS,
and clinician determined response to therapy was similar
between the other groups included in our statistical mod-
els. While they are not perfectly matched groups from a
prognostic point of view, we felt they are similar enough
for inclusion into our analysis. Further limitations of
included trials based on more specific prognostic factors
would have made any analysis impossible given the vari-
ety of different prognostic scores available for metastatic
renal cell carcinoma.
There are several important strengths and limitations to
consider when interpreting our analysis. Strengths include
our extensive searching and successful contact with
authors for clarifications and in one case, access to indi-
vidual patient data. Our data analysis approach used a
strategy that permits strong inferences about the relative
effectiveness of interventions in the absence of head-to-
head direct evidence. While head-to-head trials remain
the highest level of evidence of therapeutic effectiveness,
the method we employed has demonstrated compara-
tively consistent findings between this indirect method
and head-to-head trials [36,37]. Limitations of our review
include the absence of head-to-head trials, the potential
that other trials exist that we were unable to identify, and
the small number of included studies, thus negating the
possibility of exploring possible sub-group analyses and
exploring heterogeneity among study populations.
Indeed, such analyses can only be undertaken when there
are a large number of included studies.
Our method of analysis employed the adjusted indirect
comparisons meta-analysis method. This method may be
unfamiliar to some readers. Strengths of this method are
that it borrows strength from each trial and maintains the
benefits of randomization. Clinical, as well as statistical,
rationale is required for combining treatments. Head-to-
head (direct comparisons) trials remain the highest level
of evidence of therapeutic effectiveness and in our review
the only head-to-head trials compared these new thera-
pies versus cytokine therapy, IFN-α. While our compara-
Geometric distribution of adjusted indirect comparisonsFigur  4
Geometric distribution of adjusted indirect comparisons.
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for appropriate new clinical trials that examine the direct
relative effectiveness of these interventions and also exam-
ine the combined effectiveness of these interventions.
There has been a recent public outcry over access to these
mRCC interventions in the UK. The UK National Institute
for Clinical Excellence (NICE) has issued provisional
guidance not to recommend any of the drugs on the
National Health Service due to their cost [11]. Our review
finds that the clinical benefits of these interventions are
clear. However, NICE evaluated the cost of the drugs per
quality adjusted life year (QALY) and found all four treat-
ments exceeding the Institute's £30,000 threshold (beva-
cizumab £171,301, sorafenib tosylate £102,498,
sunitinib £71,462, temsirolimus £94,385). This troubling
finding indicates two important public health challenges:
1) drugs need to be available at reduced costs; and 2)
thresholds for cost-effectiveness need to be adjusted
according to relative clinical efficacy [38]. In May 2009,
NICE will issue final guidance that will take into account
new supplementary criteria to be applied in drugs used at
'End of Life', and because of this it is expected that one or
more of the reviewed drugs will be recommended. It is dif-
ficult to envision our own clinical decision-making, if cost
alone were the deciding factor.
Conclusion
The findings of our study raise intriguing questions about
the future of treatment options for mRCC. Sunitinib, bev-
acizumab, and temsirolimus all offer improved PFS com-
pared to IFN-α. The current availability of these active
agents allows new treatment options and strategies to
extend PFS, but in some settings are too expensive for
public availability. The optimal treatment strategy in
mRCC is likely to be defined in future randomized trials
that should examine combination therapies of these
active agents.
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